Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.

Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.

Ann Rheum Dis. 2014 Oct;73(10):1819-25. doi: 10.1136/annrheumdis-2013-203425.

PMID:
23852807
2.

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.

Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J.

Arthritis Res Ther. 2008;10(5):R104. doi: 10.1186/ar2496.

3.

Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation.

Pedersen SJ, Chiowchanwisawakit P, Lambert RG, Østergaard M, Maksymowych WP.

J Rheumatol. 2011 Jul;38(7):1349-54. doi: 10.3899/jrheum.100925.

PMID:
21459937
4.

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Baraliakos X, Haibel H, Listing J, Sieper J, Braun J.

Ann Rheum Dis. 2014 Apr;73(4):710-5. doi: 10.1136/annrheumdis-2012-202698.

PMID:
23505240
5.

Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis.

Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP.

Arthritis Rheum. 2011 Aug;63(8):2215-25. doi: 10.1002/art.30393.

6.

Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation.

Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG.

Arthritis Rheum. 2009 Jan;60(1):93-102. doi: 10.1002/art.24132.

7.
8.
9.

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.

Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J.

Rheumatology (Oxford). 2007 Sep;46(9):1450-3.

10.

Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.

Maksymowych WP, Morency N, Conner-Spady B, Lambert RG.

Ann Rheum Dis. 2013 Jan;72(1):23-8. doi: 10.1136/annrheumdis-2011-200859.

PMID:
22562977
11.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

12.

MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis.

van der Heijde D, Machado P, Braun J, Hermann KG, Baraliakos X, Hsu B, Baker D, Landewé R.

Ann Rheum Dis. 2012 Mar;71(3):369-73. doi: 10.1136/annrheumdis-2011-200208.

PMID:
21979001
13.
14.

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.

Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D.

Arthritis Rheum. 2003 Apr;48(4):1126-36.

15.

The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.

Kang KY, Ju JH, Park SH, Kim HY.

Rheumatology (Oxford). 2013 Apr;52(4):718-26. doi: 10.1093/rheumatology/kes364.

16.

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.

van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group..

Arthritis Rheum. 2008 Oct;58(10):3063-70. doi: 10.1002/art.23901.

17.

Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis.

Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D.

Ann Rheum Dis. 2010 Aug;69(8):1465-70. doi: 10.1136/ard.2009.124206.

PMID:
20498215
18.

The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.

Kang KY, Lee KY, Kwok SK, Ju JH, Park KS, Hong YS, Kim HY, Park SH.

Joint Bone Spine. 2011 Mar;78(2):188-93. doi: 10.1016/j.jbspin.2010.05.010.

PMID:
20621536
19.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

20.

Bone loss in ankylosing spondylitis: does syndesmophyte formation have an influence on bone density changes?

Kaya A, Ozgocmen S, Kamanli A, Ardicoglu O.

Med Princ Pract. 2009;18(6):470-6. doi: 10.1159/000235897.

Items per page

Supplemental Content

Support Center